TokenPost·
Santen Pharmaceutical First-Half Revenue Rises 3.9% to ¥143.289 Billion
Basic earnings per share was ¥48.05 for the six months ended Sept. 30, 2026. Santen kept its fiscal 2027 revenue and operating profit forecasts unchanged.
More news
- TokenPostAnchorage Digital Seeks Swap Dealer Registration, Plans Bitcoin and Ether Options
- TokenPostWonder Says It Confidentially Filed for an Initial Public Offering
- TokenPostSilvaco Group Beats Q3 EPS Estimate as Revenue Falls 12.7%
- TokenPostSNDK Liquidations Reach $14.27 Million in One Hour, Mostly Longs
- TokenPostEther.fi Leads Crypto Decliners With 13.45% Drop to $0.526
- TokenPostU.S. Forces Have Iran Strike Plans Ready, With Thousands on Standby